242 related articles for article (PubMed ID: 35058314)
1. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
[TBL] [Abstract][Full Text] [Related]
3. TIGIT in cancer immunotherapy.
Chauvin JM; Zarour HM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
[TBL] [Abstract][Full Text] [Related]
4. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
5. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
6. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
[TBL] [Abstract][Full Text] [Related]
7. Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K
Iwamoto N; Sasaki J; Ohno S; Aoki K; Usui Y; Inuki S; Ohno H; Oishi S
Bioorg Med Chem; 2024 Feb; 99():117585. PubMed ID: 38219557
[TBL] [Abstract][Full Text] [Related]
8. TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry.
Saito M; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):157-162. PubMed ID: 35736625
[TBL] [Abstract][Full Text] [Related]
9. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
[TBL] [Abstract][Full Text] [Related]
10. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
11. TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells.
Vendrame E; Seiler C; Ranganath T; Zhao NQ; Vergara R; Alary M; Labbé AC; Guédou F; Poudrier J; Holmes S; Roger M; Blish CA
AIDS; 2020 May; 34(6):801-813. PubMed ID: 32028328
[TBL] [Abstract][Full Text] [Related]
12. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
13. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
[TBL] [Abstract][Full Text] [Related]
14. [Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].
Wu J; Ren D; Bi H; Yi B; Wang H
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):819-827. PubMed ID: 36419396
[TBL] [Abstract][Full Text] [Related]
15. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
Lupo KB; Yao X; Borde S; Wang J; Torregrosa-Allen S; Elzey BD; Utturkar S; Lanman NA; McIntosh M; Matosevic S
Nat Commun; 2024 Mar; 15(1):1909. PubMed ID: 38429294
[TBL] [Abstract][Full Text] [Related]
16. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies.
Hasan MF; Campbell AR; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Cash CA; Eloriaga JE; Kumar S; Andersen BW; Naeimi Kararoudi M; Tullius BP; Lee DA; Copik AJ
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38081778
[TBL] [Abstract][Full Text] [Related]
17. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
[TBL] [Abstract][Full Text] [Related]
18. Blocking TIGIT/CD155 signalling reverses CD8
Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
[TBL] [Abstract][Full Text] [Related]
19. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T
Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876
[TBL] [Abstract][Full Text] [Related]
20. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
